Since its massive Shire acquisition in 2019, Takeda has been focused on paying off tens of billions in debt. But since it's leaned on asset sales to gin up cash, skeptics had begun wondering whether the company could meet its debt payment goals in the long run.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,